# Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

> **NCT01114555** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Bevacizumab, Irinotecan and Temozolomide

## Key facts

- **NCT ID:** NCT01114555
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-29
- **Primary completion:** 2018-11-02
- **Final completion:** 2018-11-02
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01114555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01114555, "Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01114555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*